Sun Pharmaceutical Industries, Inc. (Sun Pharma) Initiates Voluntary U.S. Nationwide Recall of DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL Due To Potential Presence[...]

On May 13, 2026, Sun Pharma voluntarily recalled one batch of DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL, Lot # HAG2581B, Expiration 05/2027 (675 vials). The single batch of 675 vials is being recalled due to the detection of glass particles in some vials during production.

If glass particles are administered through the veins, they may pose a risk to patient safety including local irritation or swelling in response to the foreign material. More serious potential risks could include blockage of blood vessels and life-threatening blood clot events. To date, Sun Pharma has not received any reports of adverse events related to this batch. Sun Pharma has thoroughly investigated the source of the problem and has taken corrective and preventative actions.

Doxorubicin Hydrochloride Liposome Injection is packaged in translucent, red liposomal dispersion in 25 mL glass, single-dose vials for NDC 72603-200-01. The affected DOXOrubicin Hydrochloride Liposome Injection batch is Batch HAG2581B, Expiration 05/31/2027. The product can be identified by the label (Aisling Label), each vial is labeled to indicate the name of the product: DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL, NDC 72603-200-01 Lot# HAG2581B, Expiration 05/31/2027.

Sun Pharma is notifying its distributor and customers by express overnight mail and is arranging for return/replacement etc. of all recalled products.

Users that have the product should stop using and return to place of purchase or discard the product. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product. To report suspected adverse events, contact NorthStar Rx LLC at 1-800-206-7821

Customers with questions regarding this recall can contact Inmar Inc., (Sun Pharma's recall processor) by 855-745-9357, Monday through Friday between 8:30 am and 5:00 pm, U.S. Eastern Time, or via [email protected].

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.

• Complete and submit the report Online
• Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Sources:

• U.S. Food and Drug Administration Recall Information Search. Retrieved May 18th, 2026, from https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sun-pharmaceutical-industries-inc-sun-pharma-initiates-voluntary-us-nationwide-recall-doxorubicin?utm_medium=email&utm_source=govdelivery